(Q51168908)

31 March 2018

title

Nationwide study of antipsychotic use among community-dwelling persons with Alzheimer's disease in Finland. (English)

1 reference

31 March 2018

0 references

1 reference

6

Sirpa Hartikainen

1 reference

31 March 2018

2

J Simon Bell

1 reference

31 March 2018

Piia Lavikainen

3

object named as

Piia Lavikainen

1 reference

31 March 2018

Raimo Sulkava

5

object named as

Raimo Sulkava

1 reference

31 March 2018

Marja-Liisa Laitinen

1

object named as

Marja-Liisa Laitinen

1 reference

31 March 2018

author name string

Eija Lönnroos

4

1 reference

31 March 2018

publication date

26 August 2011

1 reference

31 March 2018

International Psychogeriatrics

published in

1 reference

31 March 2018

volume

23

1 reference

31 March 2018

issue

10

1 reference

31 March 2018

page(s)

1623-1631

1 reference

31 March 2018

Metabolic changes associated with second-generation antipsychotic use in Alzheimer's disease patients: the CATIE-AD study

cites work

1 reference

https://api.crossref.org/works/10.1017%2FS1041610211001621

The association between class of antipsychotic and rates of hospitalization: results of a retrospective analysis of data from the 2005 Medicare current beneficiary survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610211001621

Trends in antipsychotic use in dementia 1999-2007.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610211001621

Mortality risk in patients with dementia treated with antipsychotics versus other psychiatric medications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610211001621

High concordance between self-reported medication and official prescription database information.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610211001621

Antipsychotic drug use and mortality in older adults with dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610211001621

Use of strong opioids among community-dwelling persons with and without Alzheimer's disease in Finland.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610211001621

Adverse Drug Events in Cognitively Impaired Elderly Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610211001621

The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610211001621

A randomised, blinded, placebo-controlled trial in dementia patients continuing or stopping neuroleptics (the DART-AD trial)

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610211001621

Atypical antipsychotics: Part II: Adverse effects, drug interactions, and costs

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610211001621

Expert opinion on the management of behavioural and psychological symptoms of dementia (BPSD) and investigation into prescribing practices in the UK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610211001621

Use of antipsychotic medications in older home-care patients. Report from nine European countries.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610211001621

Clinical progression of moderate-to-severe Alzheimer's disease and caregiver burden: a 12-month multicenter prospective observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610211001621

Antipsychotics for behavioural and psychological problems in elderly people with dementia: a systematic review of adverse events

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610211001621

Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610211001621

Validity of the Finnish Prescription Register for measuring psychotropic drug exposures among elderly finns: a population-based intervention study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610211001621

Antipsychotic use and the risk of hip/femur fracture: a population-based case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610211001621

Position statement of the American Association for Geriatric Psychiatry regarding principles of care for patients with dementia resulting from Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610211001621

Systematic review of psychological approaches to the management of neuropsychiatric symptoms of dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610211001621

Psychotropics among the home-dwelling elderly--increasing trends.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610211001621

Risk of death in elderly users of conventional vs. atypical antipsychotic medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610211001621

Use of psychotropics among home-dwelling nondemented and demented elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1041610211001621

inferred from DOI database lookup

7 January 2021

based on heuristic

Change in psychotropic drug use among community-dwelling people aged 75 years and older in Finland: repeated cross-sectional population studies

1 reference

https://api.crossref.org/works/10.1017%2FS1041610211001621

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1017/S1041610211001621

1 reference

31 March 2018

1 reference

31 March 2018